Aurinia Pharmaceuticals to Release First Quarter 2018 Financial Results on May 10, 2018
Conference Call and webcast to follow
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced that it will release its first quarter 2018 financial
results on Thursday, May 10, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the
company’s first quarter 2018 financial results and provide a general business update.
The conference call and webcast is scheduled for May 10, 2018 at 4:30pm EDT. In order to participate in the conference call,
please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio webcast can be accessed under "News/Events” through the
“Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient
populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing
voclosporin, an investigational drug, for the treatment of LN, FSGS and DES. The company is headquartered in Victoria, BC and
focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.
We seek safe harbor.
Aurinia Pharmaceuticals Inc.
Investor Contact:
Celia Economides
VP, Corporate & Public Affairs
IR@auriniapharma.com
or
Media:
Christopher Hippolyte, 212-364-0458
Christopher.hippolyte@inventivhealth.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180501006837/en/